Bone is not static tissue—it continuously remodels through a dance of osteoblasts building new matrix and osteoclasts clearing old material.
Bone is not static tissue—it continuously remodels through a dance of osteoblasts building new matrix and osteoclasts clearing old material. Osteoporosis occurs when remodelling becomes imbalanced, with too much removal and insufficient replacement, leaving a porous, fragile architecture vulnerable to fracture. Placental mesenchymal stem cells have attracted research interest because they can differentiate into osteoblasts, potentially helping restore bone-forming capacity. The mechanism appears to involve both direct cellular replacement of bone-building cells and the release of signalling molecules (cytokines) that shift the remodelling ratio back toward deposition. Early-stage trials are exploring whether cell therapy can slow or partially reverse the density loss that typically accelerates after oestrogen withdrawal in post-menopausal women, though robust efficacy data remain limited.
| Coût indicatif · Bulgarie (UE) | €3,000–€8,000 |
|---|---|
| Gamme des coûts du marché mondial | €4,600–€7,350 (dvcstem.com) |
| Principaux types de cellules étudiés | MSC de la membrane amniotique |
| Statut d'approbation | Investigationnel |
| Essais enregistrés (ClinicalTrials.gov) | 14 · 2 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
A review of registered clinical trials identified 14 completed or published studies in osteoporosis using cell-based approaches, predominantly with placental MSCs, alongside 2 currently recruiting trials. Trial sizes have ranged from 20 to 120 participants. Several small studies report modest improvements in bone mineral density (typically 3–8% change from baseline over 12–24 months) and some reduction in fracture markers, though methodological heterogeneity limits direct comparison. No large, multi-centre, phase III efficacy trial has yet reported.
Depending on assessment, a Osteoporosis & Bone Health protocol may draw on:
Direct costs for cell therapy in osteoporosis clinics typically fall between €4,000 and €7,500 per treatment course, depending on cell type, expansion protocols, and delivery method. Imaging (DXA scans, sometimes CT) and baseline bone-metabolism blood panels add €500–1,200. Long-term monitoring costs, including serial imaging and repeated treatments if needed, can accumulate; many centres recommend follow-up assessment at 6 and 12 months, each adding investigation charges.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Osteoporosis & Bone Health cost-by-country breakdown, or compare the best countries for Osteoporosis & Bone Health →
Before booking, check safety & regulation, the recovery climate, si vous pourriez être un candidat, and which cell type fits Osteoporosis & Bone Health.
FAQ complet Ostéoporose et Santé Osseuse → · Décomposition des coûts Ostéoporose et Santé Osseuse →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Suis-je un candidat? · Quel type de cellule? · Types of clinics & best countries · Calculatrice de coûts
Médicalement examiné par l'équipe éditoriale de StemCellAtlas avec Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) de la clinique partenaire Stem Plus (Sofia), selon les directives ISSCR, FDA et EMA. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite